Topiroxostat

Topiroxostat
Clinical data
Trade names	Topiloric, Uriadec
ATC code	None;
Legal status
Legal status	Approved in Japan;
Identifiers
	IUPAC name 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile;
CAS Number	577778-58-6;
PubChem CID	5288320;
ChemSpider	4450517;
Chemical and physical data
Formula	C13H8N6
Molar mass	248.24 g/mol
3D model (JSmol)	Interactive image;
	SMILES C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N;
	InChI InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19); Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N;

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.^[1] It was approved for use in Japan in June 2013.^[1]

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.^[2]

References

1 2 "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22.
↑ Hosoya, Tatsuo; Ohno, Iwao; Nomura, Shinsuke; Hisatome, Ichiro; Uchida, Shunya; Fujimori, Shin; Yamamoto, Tetsuya; Hara, Shigeko (2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. doi:10.1007/s10157-014-0935-8. PMC 4271138.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmda-1] 1 2 "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22.

[2] Hosoya, Tatsuo; Ohno, Iwao; Nomura, Shinsuke; Hisatome, Ichiro; Uchida, Shunya; Fujimori, Shin; Yamamoto, Tetsuya; Hara, Shigeko (2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. doi:10.1007/s10157-014-0935-8. PMC 4271138.